Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8166320.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.
Medical subject headings
- Behavior Therapy
- Haloperidol
- Schizophrenia